Research published in melanoma management finds that 99% of patients with uveal melanoma tested with decisiondx®-um gain value from the results

Friendswood, texas--( business wire )--castle biosciences, inc. (nasdaq: cstl), a company improving health through innovative tests that guide patient care, today announced the publication of a study completed in collaboration with the melanoma research foundation (mrf) in which most patients diagnosed with uveal melanoma (um) indicated their desire for prognostic testing at diagnosis, reported finding value in their test result and experienced lower decision regret, regardless of whether their test result indicated that their um tumor was at a high or low risk of metastasis. the study, titled “uveal melanoma patient attitudes towards prognostic testing using gene expression profiling,” was published in melanoma management and can be viewed on castle's website.
CSTL Ratings Summary
CSTL Quant Ranking